Literature DB >> 301774

Estrogen receptor and proteolytic activity in human breast tumor nuclei.

R E Garola, W L McGuire.   

Abstract

We have previously found that human breast cancer cells in tissue culture contain estrogen receptor in their nuclei despite the absence of estrogen. We have now investigated solid human breast cancer biopsies and find that proteolytic activities in extracts from the nuclear pellets of these biopsies interfere with or prevent the measurement of nuclear estrogen receptor when the protamine assay is used. However, the problems of receptor degradation can be avoided by the use of a hydroxylapatite assay.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 301774

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Inactivation of oestrogen receptor in vitro by nuclear dephosphorylation.

Authors:  F Auricchio; A Migliaccio; A Rotondi
Journal:  Biochem J       Date:  1981-02-15       Impact factor: 3.857

2.  Unoccupied binding sites for oestrogen in nuclei of a breast tumour cell line (MCF-7).

Authors:  A Geier; M Haimsohn; Z Malik; B Lunenfeld
Journal:  Biochem J       Date:  1981-12-15       Impact factor: 3.857

3.  Translocation of hepatic cytosol androgen receptor to the nucleus in vivo in male rats.

Authors:  M Ota; N Sato; S Takahashi; S Ono
Journal:  Experientia       Date:  1981-03-15

4.  Evidence for the origin of the unoccupied oestrogen receptor in nuclei of a human breast-cancer cell line (MCF-7).

Authors:  A Geier; M Haimsohn; B Lunenfeld
Journal:  Biochem J       Date:  1982-03-15       Impact factor: 3.857

5.  Estrogen and progesterone receptors in human uterus and oviduct.

Authors:  A Lukola; R Punnonen
Journal:  J Endocrinol Invest       Date:  1983-06       Impact factor: 4.256

6.  Effect of progesterone pretreatment on the uptake of estradiol-17 beta by the uterine epithelium of the rat.

Authors:  M A Vass; B Green
Journal:  Cell Tissue Res       Date:  1979-10-02       Impact factor: 5.249

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.